It’s been a turbulent few years for the pharmaceutical industry. The effects of the global pandemic and subsequent rush to develop safe, effective vaccines have sent shockwaves through the industry, impacting everything from clinical trials and drug development to launch activities and sales figures. Now, as 2022 slips behind us and we take pharma industry lessons learned into a new year, many publications are asking what pharmaceutical industry trends we might expect from the next one.
European Pharmaceutical Manufacturer convened a roundtable of industry experts to examine the key learnings from 2022. Tony Page, Within3’s SVP of Insight Analytics, joined experts from Recipharm, Lonza, Sirio Europe and UPS Healthcare to offer his takeaways from another eventful year.
“In 2022 we saw the initial phase of the health crisis subside, and life science companies accelerated tech adoption to manage everything from supply chains to clinical trial processes. In 2022, organizations embraced decentralized clinical trials, digital technology and tools across the product development process, and earned heightened levels of patient trust.” – Tony Page, SVP of Insight Analytics, Within3
Page was also invited to participate in another roundtable discussion for European Pharmaceutical Manufacturer, assessing the industry trends to watch out for in the year ahead.
“As we look to the year ahead, companies must lean further into what worked. Be wary of complacency – organizations that are content with the status quo will be outperformed by those who prioritize areas where they can see the most acceleration. This means elevating insights management to a main strategic pillar.” – Tony Page, SVP of Insight Analytics, Within3
You can read all of EPM’s predictions for 2023.